Михаил Владимирович Благосклонный
Blagosklonny, Mikhail V.
VIAF ID: 53502819 (Personal)
Permalink: http://viaf.org/viaf/53502819
Preferred Forms
- 100 1 _ ‡a Blagosklonny, Mikhail V.
- 100 1 _ ‡a Blagosklonny, Mikhail V.
-
- 100 1 _ ‡a Blagosklonny, Mikhail V.
- 100 0 _ ‡a Михаил Владимирович Благосклонный
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Cell cycle checkpoints and cancer, c2001: | |
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death | |
MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer | |
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. | |
The mystery of the ketogenic diet: benevolent pseudo-diabetes | |
NCI's provocative questions on cancer: some answers to ignite discussion | |
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis | |
A new science-business paradigm in anticancer drug development. | |
Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors | |
No restriction points in life and science. | |
A node between proliferation, apoptosis, and growth arrest | |
Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs | |
Oncogenic resistance to growth-limiting conditions | |
Overcoming limitations of natural anticancer drugs by combining with artificial agents | |
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. | |
p21 (CDKN1A) is a negative regulator of p53 stability. | |
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 | |
p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. | |
P53: an ubiquitous target of anticancer drugs | |
p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect | |
p53 inhibits hypoxia-inducible factor-stimulated transcription | |
p53 is associated with cellular microtubules and is transported to the nucleus by dynein | |
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. | |
Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. | |
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. | |
Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? | |
Paradoxes of senolytics | |
Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection | |
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms | |
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. | |
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive | |
The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors | |
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs | |
Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. | |
Progeria, rapamycin and normal aging: recent breakthrough | |
Program-like aging and mitochondria: instead of random damage by free radicals | |
Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. | |
Prospective strategies to enforce selectively cell death in cancer cells | |
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1) | |
Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. | |
Proteasome-dependent regulation of p21WAF1/CIP1 expression | |
Pseudo-DNA damage response in senescent cells | |
The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. | |
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential | |
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance | |
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. | |
Rapalogs in cancer prevention: anti-aging or anticancer? | |
Rapamycin and quasi-programmed aging: four years later | |
Rapamycin decelerates cellular senescence | |
Rapamycin extends life- and health span because it slows aging | |
Rapamycin extends maximal lifespan in cancer-prone mice | |
Rapamycin for longevity: opinion article | |
Rapamycin for the aging skin | |
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. | |
Rapamycin-induced glucose intolerance: hunger or starvation diabetes. | |
Rapamycin, proliferation and geroconversion to senescence | |
Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium | |
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats | |
Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. | |
Regulation of actin cytoskeleton in lymphocytes: PKC-delta disrupts IL-3-induced membrane ruffles downstream of Rac1. | |
Regulation of BRCA1 by protein degradation | |
The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia | |
Rejuvenating immunity: "anti-aging drug today" eight years later | |
The restriction point of the cell cycle | |
The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line. | |
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway | |
Teratogens as anti-cancer drugs | |
Tissue-selective therapy of cancer | |
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists | |
TOR-driven aging: speeding car without brakes | |
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells | |
Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion | |
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? | |
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response | |
Unwinding the loop of Bcl-2 phosphorylation | |
Validation of anti-aging drugs by treating age-related diseases | |
Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet | |
While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts | |
Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis | |
Why Iressa failed: toward novel use of kinase inhibitors (outlook). | |
Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives | |
Why the disposable soma theory cannot explain why women live longer and why we age. | |
Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance | |
Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells | |
Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells | |
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells | |
Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression |